Assessment of bortezomib induced peripheral neuropathy in multiple myeloma by the reduced Total Neuropathy Score

Leukemia and Lymphoma

Volumn 55, Issue 10, 2014, Pages 2277-2283

  Zaroulis, Chrysothea K ^a,b   Chairopoulos, Konstantinos ^b   Sachanas, Sotirios P ^c   Maltezas, Dimitris ^a   Tzenou, Tatiana ^a   Pessach, Ilias ^a   Koulieris, Efstathios ^a   Koutra, Eleni ^d   Kilindireas, Konstantinos ^e   Pangalis, Gerasimos A ^c   Kyrtsonis, Marie Christine ^a  

^a LAIKO GENERAL HOSPITAL   (Greece)

^b General Military Hospital of Athens   (Greece)

^c ATHENS MEDICAL CENTER   (Greece)

^d EVANGELISMOS HOSPITAL   (Greece)

^e NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

Bortezomib; Drug induced peripheral neuropathy; Multiple myeloma

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; PYRAZINE DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RECURRENCE; DISEASE DURATION; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; QUALITY OF LIFE; RISK FACTOR; SCORING SYSTEM; TOTAL NEUROPATHY SCORE; COMPLICATION; FOLLOW UP; MIDDLE AGED; NEUROLOGIC EXAMINATION; PERIPHERAL NERVOUS SYSTEM DISEASES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEUROLOGIC EXAMINATION; PERIPHERAL NERVOUS SYSTEM DISEASES; PYRAZINES; RISK FACTORS;

EID: 84906277975     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.873535     Document Type: Article

References (49)

1. Delforge M, Bladé J, Dimopoulos M, et al. Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues. Lancet Oncol 2010;11:1086-1095.
2. Richardson P, Hideshima T, Anderson K. Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers. Cancer Control 2003;10:361-369.
3. Russo A, Bronte G, Fulfaro F, et al. Bortezomib: a new pro-apoptotic agent in cancer treatment. Curr Cancer Drug Targets 2010;10:55-67.
4. Panwalkar A, Verstovsek S, Giles F. Nuclear factor-kappa B modulation as a therapeutic approach in hematologic malignancies. Cancer 2004;100:1578-1589.
5. Hideshima T, Ikeda H, Chauhan D, et al. Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood 2009;114:1046-1052.
6. Argyriou AA, Iconomou G, Kalofonos HP. Bortezomib induced peripheral neuropathy in multiple myeloma:a comprehensive review of the literature. Blood 2008;112:1593-1599.
7. Mujtaba T, Don QP. Advances in the understanding of mechanisms and therapeutic use of bortezomib. Discov Med 2011;12:471-480.
8. Cornblath DR, Chaudhry V, Carter K, et al. Total neuropathy score: validation and reliability study. Neurology 1999;53:1660-1664.
9. Wampler M, Miaskowski C, Hamel K, et al. The modified total neuropathy score: a clinically feasible and valid measure of taxane-induced peripheral neuropathy in women with breast cancer. J Support Oncol 2006;4:9-16.
10. Cavaletti G, Frigeni B, Lanzani F, et al. The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale. J Peripher Nerv Syst 2007;12:210-215.
11. Cavaletti G, Jann S, Pace A, et al. Multi-center assessment of the Total Neuropathy Score for chemotherapy-induced peripheral neurotoxicity. J Peripher Nerv Syst 2006;11:135-141.
12. Miguel JS, Bladé J, Boccadoro M, et al. A practical update on the use of bortezomib in the management of multiple myeloma. Oncologist 2006;11:51-61.
13. Anderson KC, Kyle RA, Dalton WS, et al. Multiple myeloma: new insights and therapeutic approaches. Hematology Am Soc Hematol Educ Program 2000:147-165.
14. Kyrtsonis M-C, Maltezas D, Koulieris E, et al. Response to bortezomib in refractory/relapsed multiple myeloma patients: a single center experience with discussion on specific issues. Asia-Pacific J Oncol Hematol 2010;2:1-11.
15. Hermans G, Clerckx B, Vanhullebusch T, et al. Interobserver agreement of Medical Research Council sum-score and handgrip strength in the intensive care unit. Muscle Nerve 2012;45:18-25.
16. Khoiny AS, Behrouz R. Critical illness polyneuropathy and criticall illness myopathy. Pract Neurol 2011;11:52-56.
17. Meijer JW, Smit AJ, Lefrandt JD, et al. Back to basics in diagnosing diabetic polyneuropathy with the tuning fork. Diabetes Care 2005;28:2201-2205.
18. Devi P, Madhu K, Ganapathy B, et al. Evaluation of efficacy and safety of gabapentin, duloxetine, and pregabalin in patients with painful diabetic peripheral neuropathy. Indian J Pharmacol 2012;4:51-56.
19. Matsuoka H, Makimura C, Koyama A, et al. Pilot study of duloxetine for cancer patients with neuropathic pain non-responsive to pregabalin. Anticancer Res 2012;32:1805-1809.
20. Rajkumar SV. Multiple myeloma: 2012 update on diagnosis, risk-stratification and management. Am J Hematol 2012;87:78-88.
21. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008;111:2516-2520.
22. Berenson JR, Jagannath S, Barlogie B, et al. Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma. Cancer 2005;104:2141-2148.
23. Badros A, Goloubeva O, Dalal JS, et al. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature. Cancer 2007;110:1042-1049.
24. Cavaletti G, Nobile-Orazio E. Bortezomib-induced peripheral neurotoxicity: still far from a painless gain. Haematologica 2007;92:1308-1310.
25. Pei XY, Dai Y, Grant S. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin Cancer Res 2004;10:3839-3852.
26. Silverman LCL, Kadambi VJ, Decoster R, et al. Model for proteasome inhibition associated peripheral neuropathy. Toxicol Pathol 2006;34:989.
27. Cavaletti G, Gilardini A, Canta A, et al. Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat. Exp Neurol 2007;204:317-325.
28. +2 is a critical determinant of Velcade (PS-341/bortezomib) cytotoxicity in myeloma cell lines. Cancer Res 2005;65:3828-3836.
29. Cavaletti G, Marmiroli P. The role of growth factors in the prevention and treatment of chemotherapy-induced peripheral neurotoxicity. Curt Drug Saf 2006;1:35-42.
30. Lindsay RM. Nerve growth factors (NGF, BDNF) enhance axonal regeneration but are not required for survival of adult sensory neurons. J Neurosci 1988;8:2394-2405.
31. Weerasuriya A, Mizisin AP. The blood-nerve barrier: structure and functional significance. Methods Mol Biol 2011;686:149-173.
32. Abe M, Sano Y, Maeda T, et al. E stablishment and characterization of human peripheral nerve microvascular methods. Mol Biol 2011;686:149-173.
33. England JD, Gronseth GS, Franklin G, et al. Distal symmetric polyneuropathy: a definition for clinical research: report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology 2005;64:199-207.
34. Carozzi VA, Canta A, Oggioni N, et al. Neurophysiological and neuropathological characterization of new murine models of chemotherapy-induced chronic peripheral neuropathies. Exp Neurol 2010;226:301-309.
35. Giannoccaro MP, Donadio V, Gomis Pèrez C, et al. Somatic and autonomic small fiber neuropathy induced by bortezomib therapy: an immunofluorescence study. Neurol Sci 2011;32:361-363.
36. Cata JP, Weng HR, Burton AW, et al. Quantitative sensory findings in patients with bortezomib-induced pain. J Pain 2007;8:296-306.
37. Richardson PG, Xie W, Mitsiades C, et al. Single-agent bortezomib in previously untreated multiple myeloma:efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol 2009;27:3518-3525.
38. Mohty B, El-Cheikh J, Yakoub-Agha I, et al. Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations. Haematologica. 2010;95:311-319.
39. Chaudhry V, Cornblath DR, Polydefkis M, et al. Characteristics of bortezomib- and thalidomide-induced peripheral neuropathy. J Peripher Nerv Syst 2008;13:275-282.
40. Grover JK, Uppal G, Raina V. The adverse effects of thalidomide in relapsed and refractory patients of multiple myeloma. Ann Oncol 2002;13:1636-1640.
41. Huynh W, Kiernan MC. Nerve conduction studies. Aust Fam Physician 2011;40:693-697.
42. Rosenberg NR, Portegies P, de Visser M, et al. Diagnostic investigation of patients with chronic polyneuropathy: evaluation of a clinical guideline. J Neurol Neurosurg Psychiatry 2001;71:205-209.
43. Richardson PG, Briemberg H, Jagannath S, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 2006;24:3113-3120.
44. Dimopoulos MA, Mateos MV, Richardson PG, et al. Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study. Eur J Haematol 2011;86:23-31.
45. Chen CI, Kouroukis CT, White D, et al. Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1570-1575.
46. Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol 2011;12:431-400.
47. Mateos MV. Subcutaneous bortezomib: a step towards optimised drug use. Lancet Oncol 2011;12:410-411.
48. Bringhen S, Larocca A, Rossi D, et al. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood 2010;116:4745-4753.
49. Velasco R, Petit J, C lapés V, et al. Neurological monitoring reduces the incidence of bortezomib-induced peripheral neuropathy in multiple myeloma patients. J Peripheral Nerv Syst 2010;15:17-25.